Keep Calm and Carry on Inhibiting the RAS — NephJC
This week, we will discuss the STOP ACEi trial, a poster from Kidney Week but published in the NEJM. Should we stop RAS inhibition at an arbitrary GFR or bravely carry on?
Related Articles
Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy
C3 glomerulopathy (C3G) is a rare disease resulting from dysregulation of the alternative pathway of complement. C3G includes C3 glomerulonephritis (C3GN) and dense deposit disease…
Apolipoprotein E in Dense Deposit Disease and C3 GN – Visual Abstract — NephJC
Is Apolipoprotein E a new biomarker for DDD and C3GN? NSMC Intern Dr Jasmine Sethi decodes the recent study visually
Shedding Light on the Dense Matter of C3 Glomerulopathy — NephJC
This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
PubMed
PubMed® comprises more than 36 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text…
Sparsentan in IgA Nephropathy : The PROTECT trial — NephJC
This week, we will discuss another IgA Nephropathy trial – Sparsentan this time. A dual endothelin antagonist and angiotensin receptor antagonist.
PubMed
PubMed® comprises more than 36 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text…
Freely Filtered 048: Putting TESTING to the Test — NephJC
Episode 048: TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because…
Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States
To estimate the cost-effectiveness of Nefecon in addition to the best supportive care (BSC) vs BSC in a hypothetical cohort of commercially insured adult patients…
Nefecon in IgA Nephropathy, the Nefigard trial — NephJC
This week, we will discuss NEFIGARD, the trial of a targeted release steroid. It reduces proteinuria in IgA nephropathy – should it upstage humble prednisone?